{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:04:38Z","timestamp":1794647078606,"version":"4.9.1"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41401-026-01928-0","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T03:26:31Z","timestamp":1789356391000},"page":"3329-3346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic cancer vaccines: development, challenges, and future perspectives"],"prefix":"10.1038","volume":"47","author":[{"given":"Di","family":"Di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan-feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-xia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Nian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-yan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1928_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi N, Jaffee EM, Yarchoan M. Recent advances in therapeutic cancer vaccines. Nat Rev Cancer. 2025;25:517\u201333.","journal-title":"Nat Rev Cancer"},{"key":"1928_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","volume":"25","author":"F Baharom","year":"2025","unstructured":"Baharom F, Hermans D, Delamarre L, Seder RA. Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment. Nat Rev Immunol. 2025;25:195\u2013211.","journal-title":"Nat Rev Immunol"},{"key":"1928_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s44178-024-00077-w","volume":"3","author":"Y Cao","year":"2024","unstructured":"Cao Y. Cancer-triggered systemic disease and therapeutic targets. Holist Integr Oncol. 2024;3:11.","journal-title":"Holist Integr Oncol"},{"key":"1928_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"1928_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222\u20136.","journal-title":"Nature"},{"key":"1928_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","volume":"43","author":"F Huber","year":"2025","unstructured":"Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2025;43:1360\u201372.","journal-title":"Nat Biotechnol"},{"key":"1928_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Ad\u00e1n-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21:257\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"1928_CR8","doi-asserted-by":"crossref","unstructured":"Wiemann B, Starnes CO. Coley\u2019s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529\u201364.","DOI":"10.1016\/0163-7258(94)90023-X"},{"key":"1928_CR9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#","volume":"55","author":"HC Hoover","year":"1985","unstructured":"Hoover HC, Surdyke MG, Dangel RB, Peters LC, Hanna MG. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 1985;55:1236\u201343.","journal-title":"Cancer"},{"key":"1928_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P van der Bruggen","year":"1991","unstructured":"van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643\u20137.","journal-title":"Science"},{"key":"1928_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1928_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"1928_CR13","doi-asserted-by":"publisher","unstructured":"Khattak A, Carlino MS, Meniawy T, Ansstas G, Taylor MH, Kim KB, et al. Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase IIb KEYNOTE-942 study. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO-26-00835.","DOI":"10.1200\/JCO-26-00835"},{"key":"1928_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.183.3.1185","volume":"183","author":"PF Robbins","year":"1996","unstructured":"Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183:1185\u201392.","journal-title":"J Exp Med"},{"key":"1928_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747\u201352.","journal-title":"Nat Med"},{"key":"1928_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572\u20136.","journal-title":"Nature"},{"key":"1928_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13404","volume":"7","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg M, Br\u00e4unlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7:13404.","journal-title":"Nat Commun"},{"key":"1928_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae595","volume":"26","author":"Y Chang","year":"2024","unstructured":"Chang Y, Wu L. CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Brief Bioinform. 2024;26:bbae595.","journal-title":"Brief Bioinform"},{"key":"1928_CR19","doi-asserted-by":"publisher","first-page":"W134","DOI":"10.1093\/nar\/gkad275","volume":"51","author":"JY Kim","year":"2023","unstructured":"Kim JY, Bang H, Noh S-J, Choi JK. DeepNeo: a webserver for predicting immunogenic neoantigens. Nucleic Acids Res. 2023;51:W134\u201340.","journal-title":"Nucleic Acids Res"},{"key":"1928_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s42256-021-00383-2","volume":"3","author":"T Lu","year":"2021","unstructured":"Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, Xiao X, et al. Deep learning-based prediction of the T cell receptor-antigen binding specificity. Nat Mach Intell. 2021;3:864\u201375.","journal-title":"Nat Mach Intell"},{"key":"1928_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae547","volume":"40","author":"D Jiang","year":"2024","unstructured":"Jiang D, Xi B, Tan W, Chen Z, Wei J, Hu M, et al. NeoaPred: a deep-learning framework for predicting immunogenic neoantigen based on surface and structural features of peptide-human leukocyte antigen complexes. Bioinformatics. 2024;40:btae547.","journal-title":"Bioinformatics"},{"key":"1928_CR22","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41587-021-01072-6","volume":"40","author":"M Arnaud","year":"2022","unstructured":"Arnaud M, Chiffelle J, Genolet R, Navarro Rodrigo B, Perez MAS, Huber F, et al. Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat Biotechnol. 2022;40:656\u201360.","journal-title":"Nat Biotechnol"},{"key":"1928_CR23","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/cancers13225801","volume":"13","author":"A Harari","year":"2021","unstructured":"Harari A, Sarivalasis A, de Jonge K, Thierry A-C, Huber F, Boudousquie C, et al. A personalized neoantigen vaccine in combination with platinum-based chemotherapy induces a T-cell response coinciding with a complete response in endometrial carcinoma. Cancers. 2021;13:5801.","journal-title":"Cancers"},{"key":"1928_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115340","volume":"210","author":"C Wang","year":"2024","unstructured":"Wang C, Yuan F. A comprehensive comparison of DNA and RNA vaccines. Adv Drug Deliv Rev. 2024;210:115340.","journal-title":"Adv Drug Deliv Rev"},{"key":"1928_CR25","doi-asserted-by":"publisher","unstructured":"Liu R, Ye R, Hu G, Chen H, Niu M, Wang R, et al. Antigen-encoding circular single-stranded DNA for cancer vaccine. Mol Ther. 2026. https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.030.","DOI":"10.1016\/j.ymthe.2026.02.030"},{"key":"1928_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02211-8","volume":"24","author":"D Chai","year":"2025","unstructured":"Chai D, Wang J, Lim JM, Xie X, Yu X, Zhao D, et al. Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity. Mol Cancer. 2025;24:12.","journal-title":"Mol Cancer"},{"key":"1928_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102035","volume":"6","author":"NJ Tursi","year":"2025","unstructured":"Tursi NJ, Tiwari S, Bedanova N, Kannan T, Parzych E, Okba N, et al. Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. Cell Rep Med. 2025;6:102035.","journal-title":"Cell Rep Med"},{"key":"1928_CR28","doi-asserted-by":"crossref","unstructured":"Personalized DNA vaccine immunogenic against melanoma. Cancer Discov. 2024;14:8\u20139.","DOI":"10.1158\/2159-8290.CD-NB2023-0082"},{"key":"1928_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang X, Goedegebuure SP, Chen MY, Mishra R, Zhang F, Yu YY, et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 2024;16:131.","journal-title":"Genome Med"},{"key":"1928_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113776","volume":"383","author":"SW Cho","year":"2025","unstructured":"Cho SW, Shin SC, Nam Y, Ahn HJ. A T7 autogene-mediated DNA vaccine platform for SARS-CoV-2: Overcoming DNA vaccine limitations with enhanced spike mRNA production. J Control Release. 2025;383:113776.","journal-title":"J Control Release"},{"key":"1928_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.adx6291","volume":"391","author":"A Romanov","year":"2026","unstructured":"Romanov A, Knappe GA, Ronsard L, Cottrell CA, Zhang YJ, Suh H, et al. DNA origami vaccines program antigen-focused germinal centers. Science. 2026;391:eadx6291.","journal-title":"Science"},{"key":"1928_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","volume":"18","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wei Y, Tian X, Wei X. Cancer vaccines: current status and future directions. J Hematol Oncol. 2025;18:18.","journal-title":"J Hematol Oncol"},{"key":"1928_CR33","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1016\/j.ymthe.2025.04.044","volume":"33","author":"L Elliott","year":"2025","unstructured":"Elliott L, Foster T, Castillo P, Mendez-Gomez H, Sayour EJ. Therapeutic mRNA vaccine applications in oncology. Mol Ther. 2025;33:2610\u20138.","journal-title":"Mol Ther"},{"key":"1928_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108015","volume":"301","author":"L Jin","year":"2025","unstructured":"Jin L, Zhou Y, Zhang S, Chen S-J. mRNA vaccine sequence and structure design and optimization: advances and challenges. J Biol Chem. 2025;301:108015.","journal-title":"J Biol Chem"},{"key":"1928_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51301-0","volume":"15","author":"J Monroe","year":"2024","unstructured":"Monroe J, Eyler DE, Mitchell L, Deb I, Bojanowski A, Srinivas P, et al. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. Nat Commun. 2024;15:8119.","journal-title":"Nat Commun"},{"key":"1928_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41586-025-09945-5","volume":"651","author":"B Rozman","year":"2026","unstructured":"Rozman B, Broennimann K, Rajan KS, Nachshon A, Saha C, Arazi T, et al. N1-Methylpseudouridine directly modulates translation dynamics. Nature. 2026;651:533\u201341.","journal-title":"Nature"},{"key":"1928_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69972-2","volume":"17","author":"H Yu","year":"2026","unstructured":"Yu H, Yang Y, Lin P, Liu C, Wen Y, Huang Z, et al. An engineered linear cap-independent mRNA vaccine with intrinsic adjuvanticity induces potent anti-tumor immunity in mice. Nat Commun. 2026;17:3205.","journal-title":"Nat Commun"},{"key":"1928_CR38","doi-asserted-by":"publisher","unstructured":"Jiang Y, Li Y, Wu T, Cao L, Xu G, Liu J, et al. GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001605.","DOI":"10.1097\/HEP.0000000000001605"},{"key":"1928_CR39","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/s12276-025-01506-0","volume":"57","author":"X Yu","year":"2025","unstructured":"Yu X, Ding P, Guo M, Tang X, Wang Z, Zhang Y, et al. Extracellular vesicle-mediated delivery of circp53 suppresses the progression of multiple cancers by activating the CypD\/TRAP\/HSP90 pathway. Exp Mol Med. 2025;57:1711\u201326.","journal-title":"Exp Mol Med"},{"key":"1928_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47905-1","volume":"15","author":"NT H\u1ed3","year":"2024","unstructured":"H\u1ed3 NT, Hughes SG, Ta VT, Phan LT, \u0110\u1ed7 Q, Nguy\u1ec5n TV, et al. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun. 2024;15:4081.","journal-title":"Nat Commun"},{"key":"1928_CR41","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","volume":"33","author":"IC Casmil","year":"2025","unstructured":"Casmil IC, Jin J, Won E-J, Huang C, Liao S, Cha-Molstad H, et al. The advent of clinical self-amplifying RNA vaccines. Mol Ther. 2025;33:2565\u201382.","journal-title":"Mol Ther"},{"key":"1928_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68364-w","volume":"17","author":"Z Feng","year":"2026","unstructured":"Feng Z, Chu L, Li Q, Zhou J, Wu P, Zhang X, et al. Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo. Nat Commun. 2026;17:1666.","journal-title":"Nat Commun"},{"key":"1928_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60959-z","volume":"16","author":"JM Johansson","year":"2025","unstructured":"Johansson JM, Du Rietz H, Hedlund H, Eriksson HC, Oude Blenke E, Pote A, et al. Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol. Nat Commun. 2025;16:5354.","journal-title":"Nat Commun"},{"key":"1928_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03681-8","volume":"23","author":"Y Wu","year":"2025","unstructured":"Wu Y, Sun G, Ren W, Gui Y, Wang C, Ye X, et al. Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model. J Nanobiotechnol. 2025;23:602.","journal-title":"J Nanobiotechnol"},{"key":"1928_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202512535","volume":"13","author":"Q Yin","year":"2026","unstructured":"Yin Q, Zhang C, Li J, Huang K, Qiu M. A rationally engineered spleen-tropic one-component lipid-mRNA complex (OncoLRC) for cancer vaccines. Adv Sci (Weinh). 2026;13:e12535.","journal-title":"Adv Sci (Weinh)"},{"key":"1928_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx5970","volume":"11","author":"H Zhang","year":"2025","unstructured":"Zhang H, Liu D, Yang K, Liang Z, Li M. Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy. Sci Adv. 2025;11:eadx5970.","journal-title":"Sci Adv"},{"key":"1928_CR47","first-page":"429","volume":"61","author":"X Chen","year":"2026","unstructured":"Chen X, Li X, Yan Y, Li Z, Li J, Xue J, et al. Splenic dendritic cell-targeting mRNA transfection of H-type ionizable lipid-based LNPs for enhancing tumor immunotherapy. Bioact Mater. 2026;61:429\u201347.","journal-title":"Bioact Mater"},{"key":"1928_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2025.139025","volume":"702","author":"Y Han","year":"2026","unstructured":"Han Y, Zhang K, Xin N, Gao X, Ma G, An J, et al. Zn-coordinated lipid nanoparticles synergistically enhance spleen-targeting delivery and elicit CD8+ T cell-mediated cancer immunotherapy. J Colloid Interface Sci. 2026;702:139025.","journal-title":"J Colloid Interface Sci"},{"key":"1928_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114742","volume":"392","author":"Y Han","year":"2026","unstructured":"Han Y, Ma G, Zhang K, Xu R, Xin N, An J, et al. Zn(II)-adjuvanted imidazole-based lipid nanoparticles for potent spleen-targeted mRNA delivery and enhanced immune activation. J Control Release. 2026;392:114742.","journal-title":"J Control Release"},{"key":"1928_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202509471","volume":"38","author":"X Duan","year":"2026","unstructured":"Duan X, Huang H, Liu S, Gu J, Qin S, Jiang S, et al. Reprogramming mRNA delivery tropism via nitrogen-to-sulfur substitution in ionizable lipids. Adv Mater. 2026;38:e09471.","journal-title":"Adv Mater"},{"key":"1928_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"1928_CR52","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025;639:1042\u201351.","journal-title":"Nature"},{"key":"1928_CR53","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics. 2020;10:6011\u201323.","journal-title":"Theranostics"},{"key":"1928_CR54","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838\u201347.","journal-title":"N Engl J Med"},{"key":"1928_CR55","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1016\/j.cell.2025.08.025","volume":"188","author":"HH Wang","year":"2025","unstructured":"Wang HH, Zaidi N. Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells. Cell. 2025;188:5121\u20133.","journal-title":"Cell"},{"key":"1928_CR56","doi-asserted-by":"publisher","first-page":"e011070","DOI":"10.1136\/jitc-2024-011070","volume":"13","author":"H Zelba","year":"2025","unstructured":"Zelba H, Shao B, Rabsteyn A, Reinhardt A, Greve C, Oenning L, et al. In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination. J Immunother Cancer. 2025;13:e011070.","journal-title":"J Immunother Cancer"},{"key":"1928_CR57","doi-asserted-by":"crossref","unstructured":"Mizukoshi E, Nakagawa H, Tamai T, Kitahara M, Fushimi K, Nio K, et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nat Commun. 2022;13:3123.","DOI":"10.1038\/s41467-022-30861-z"},{"key":"1928_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500021","volume":"12","author":"Y Xu","year":"2025","unstructured":"Xu Y, Wang B, Huang Y, Liao J, Wu C, Zhou C, et al. Targeting antigen-presenting cells to enhance the tumor-spleen immunity cycle through liposome-neoantigen vaccine. Adv Sci (Weinh). 2025;12:e2500021.","journal-title":"Adv Sci (Weinh)"},{"key":"1928_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123754","volume":"327","author":"Y Luo","year":"2026","unstructured":"Luo Y, Li Q, Zhou S, Oh H, Jablonski J, Song Y, et al. Lipid nanoparticles that co-deliver poly(I:C) and short peptide antigens elicit anti-tumor responses with vaccination. Biomaterials. 2026;327:123754.","journal-title":"Biomaterials"},{"key":"1928_CR60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409978122","volume":"122","author":"K Song","year":"2025","unstructured":"Song K, Nguyen DC, Wang Y, Jokonya S, Yazdani O, Sellers DL, et al. Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses. Proc Natl Acad Sci USA. 2025;122:e2409978122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1928_CR61","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s43018-025-00998-z","volume":"6","author":"EM Thompson","year":"2025","unstructured":"Thompson EM, Ashley DM, Ayasoufi K, Norberg P, Archer G, Buckley ED, et al. A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial. Nat Cancer. 2025;6:1559\u201369.","journal-title":"Nat Cancer"},{"key":"1928_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68324-4","volume":"17","author":"AL Huff","year":"2026","unstructured":"Huff AL, Haldar SD, Girgis AA, Wang HH, Danilova L, Heumann T, et al. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat Commun. 2026;17:1538.","journal-title":"Nat Commun"},{"key":"1928_CR63","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1038\/s41591-025-03995-y","volume":"31","author":"M Baretti","year":"2025","unstructured":"Baretti M, Kirk AM, Ladle BH, Kamdar Z, Bendinelli KJ, Ho WJ, et al. A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial. Nat Med. 2025;31:4246\u201355.","journal-title":"Nat Med"},{"key":"1928_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jconrel.2023.05.044","volume":"359","author":"X Qin","year":"2023","unstructured":"Qin X, Yang T, Xu H, Zhang R, Zhao S, Kong L, et al. Dying tumor cells-inspired vaccine for boosting humoral and cellular immunity against cancer. J Control Release. 2023;359:359\u201372.","journal-title":"J Control Release"},{"key":"1928_CR65","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.3390\/ijms25147509","volume":"25","author":"S Zanotta","year":"2024","unstructured":"Zanotta S, Galati D, De Filippi R, Pinto A. Enhancing dendritic cell cancer vaccination: the synergy of immune checkpoint inhibitors in combined therapies. Int J Mol Sci. 2024;25:7509.","journal-title":"Int J Mol Sci"},{"key":"1928_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202408685","volume":"36","author":"Q Cheng","year":"2024","unstructured":"Cheng Q, Zhang T, Wang Q, Wu X, Li L, Lin R, et al. Photocatalytic carbon dots-triggered pyroptosis for whole cancer cell vaccines. Adv Mater. 2024;36:e2408685.","journal-title":"Adv Mater"},{"key":"1928_CR67","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2213132","volume":"12","author":"N Kajihara","year":"2023","unstructured":"Kajihara N, Tanaka Y, Takeuchi R, Kobayashi T, Tanji M, Ataka T, et al. Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells. Oncoimmunology. 2023;12:2213132.","journal-title":"Oncoimmunology"},{"key":"1928_CR68","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1039\/D5MH01849H","volume":"13","author":"H Han","year":"2026","unstructured":"Han H, Yu D, Shi P, Zhang H, Jia H. Development of a whole cell vaccine to activate dendritic cells using polyvalent CpG. Mater Horiz. 2026;13:1603\u20138.","journal-title":"Mater Horiz"},{"key":"1928_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202208923","volume":"35","author":"Y Li","year":"2023","unstructured":"Li Y, Zhang H, Wang R, Wang Y, Li R, Zhu M, et al. Tumor cell nanovaccines based on genetically engineered antibody-anchored membrane. Adv Mater. 2023;35:e2208923.","journal-title":"Adv Mater"},{"key":"1928_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2520276123","volume":"123","author":"S Guo","year":"2026","unstructured":"Guo S, Lei Q, Chen Y, Yang J, Lin J, Brinker CJ, et al. Oocyte-inspired universal whole-cell vaccines against tumor heterogeneity. Proc Natl Acad Sci USA. 2026;123:e2520276123.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1928_CR71","doi-asserted-by":"publisher","first-page":"124112","DOI":"10.1016\/j.biomaterials.2026.124112","volume":"331","author":"Z Lu","year":"2026","unstructured":"Lu Z, Gu W, Jiang F, Chen L, Chen S, Feng J, et al. STING-activating & ICD dual-response whole tumor cell vaccine amplifies TNBC immunotherapy. Biomaterials. 2026;331:124112.","journal-title":"Biomaterials"},{"key":"1928_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1715761","volume":"17","author":"A Urman","year":"2026","unstructured":"Urman A, Ding Y, Durham J, Wang H, Qi H, Narang A, et al. Safety and immunologic impact of neoadjuvant\/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Front Immunol. 2026;17:1715761.","journal-title":"Front Immunol"},{"key":"1928_CR73","doi-asserted-by":"crossref","unstructured":"Khan ST, Montroy J, Forbes N, Bastin D, Kennedy MA, Diallo JS, et al. Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. BMJ Open. 2020;10:e034714.","DOI":"10.1136\/bmjopen-2019-034714"},{"key":"1928_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021;6:26.","journal-title":"Signal Transduct Target Ther"},{"key":"1928_CR75","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","volume":"10","author":"S Peng","year":"2022","unstructured":"Peng S, Chen S, Hu W, Mei J, Zeng X, Su T, et al. Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res. 2022;10:728\u201344.","journal-title":"Cancer Immunol Res"},{"key":"1928_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58289-1","volume":"16","author":"I Heras-Murillo","year":"2025","unstructured":"Heras-Murillo I, Ma\u00f1anes D, Munn\u00e9 P, N\u00fa\u00f1ez V, Herrera J, Catal\u00e1-Montoro M, et al. Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse. Nat Commun. 2025;16:3369.","journal-title":"Nat Commun"},{"key":"1928_CR77","doi-asserted-by":"publisher","first-page":"e012405","DOI":"10.1136\/jitc-2025-012405","volume":"13","author":"P Liu","year":"2025","unstructured":"Liu P, Zhou Z, Li Y, Zhang T, Su X, Xu Y, et al. PROTAC-based nanoantigens promote cross-presentation and trafficking of dendritic cell vaccine for enhanced antitumor efficacy. J Immunother Cancer. 2025;13:e012405.","journal-title":"J Immunother Cancer"},{"key":"1928_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40886-7","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Bhatta R, Liu Y, Bo Y, Elosegui-Artola A, Wang H. Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine. Nat Commun. 2023;14:5049.","journal-title":"Nat Commun"},{"key":"1928_CR79","doi-asserted-by":"crossref","unstructured":"Hesemans E, Saffarzadeh N, Maksoudian C, Izci M, Chu T, Rios Luci C, et al. Cu-doped TiO2 nanoparticles improve local antitumor immune activation and optimize dendritic cell vaccine strategies. J Nanobiotechnol. 2023;21:87.","DOI":"10.1186\/s12951-023-01844-z"},{"key":"1928_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207017","volume":"10","author":"J Xu","year":"2023","unstructured":"Xu J, Liu H, Wang T, Wen Z, Chen H, Yang Z, et al. CCR7 mediated mimetic dendritic cell vaccine homing in lymph node for head and neck squamous cell carcinoma therapy. Adv Sci. 2023;10:e2207017.","journal-title":"Adv Sci"},{"key":"1928_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59840-w","volume":"16","author":"C-J Chao","year":"2025","unstructured":"Chao C-J, Zhang E, Trinh DN, Udofa E, Lin H, Silvers C, et al. Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization. Nat Commun. 2025;16:4578.","journal-title":"Nat Commun"},{"key":"1928_CR82","doi-asserted-by":"publisher","first-page":"e000772","DOI":"10.1136\/jitc-2020-000772","volume":"8","author":"SP Lau","year":"2020","unstructured":"Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, et al. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer. 2020;8:e000772.","journal-title":"J Immunother Cancer"},{"key":"1928_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66092-1","volume":"16","author":"S Kucukcelebi","year":"2025","unstructured":"Kucukcelebi S, van \u2019t Land FR, van der Burg SH, Eskens FALM, Homs MYV, Willemsen M, et al. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Nat Commun. 2025;16:10609.","journal-title":"Nat Commun"},{"key":"1928_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48073-y","volume":"15","author":"RG Everson","year":"2024","unstructured":"Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, et al. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat Commun. 2024;15:3882.","journal-title":"Nat Commun"},{"key":"1928_CR85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8:149.","journal-title":"Signal Transduct Target Ther"},{"key":"1928_CR86","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. 2021;11:2998\u20133007.","journal-title":"Cancer Discov"},{"key":"1928_CR87","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","volume":"3","author":"R Ramlau","year":"2008","unstructured":"Ramlau R, Quoix E, Rolski J, Pless M, Lena H, L\u00e9vy E, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV Non-small cell lung cancer. J Thorac Oncol. 2008;3:735\u201344.","journal-title":"J Thorac Oncol"},{"key":"1928_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102715","volume":"67","author":"DM Filippini","year":"2026","unstructured":"Filippini DM, Le Tourneau C. Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. Transl Oncol. 2026;67:102715.","journal-title":"Transl Oncol"},{"key":"1928_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732166","volume":"11","author":"H Lauterbach","year":"2021","unstructured":"Lauterbach H, Schmidt S, Katchar K, Qing X, Iacobucci C, Hwang A, et al. Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform. Front Oncol. 2021;11:732166.","journal-title":"Front Oncol"},{"key":"1928_CR90","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"1928_CR91","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000533650","volume":"13","author":"GK Abou-Alfa","year":"2024","unstructured":"Abou-Alfa GK, Galle PR, Chao Y, Erinjeri J, Heo J, Borad MJ, et al. PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer. 2024;13:248\u201364.","journal-title":"Liver Cancer"},{"key":"1928_CR92","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1200\/JCO-25-01346","volume":"43","author":"MK Wong","year":"2025","unstructured":"Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Mu\u00f1oz Couselo E, et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE). J Clin Oncol. 2025;43:3589\u201399.","journal-title":"J Clin Oncol"},{"key":"1928_CR93","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/neuonc\/noaf079","volume":"27","author":"PY Wen","year":"2025","unstructured":"Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L, Grossman SA, et al. A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. Neuro Oncol. 2025;27:2617\u201331.","journal-title":"Neuro Oncol"},{"key":"1928_CR94","doi-asserted-by":"publisher","first-page":"e010675","DOI":"10.1136\/jitc-2024-010675","volume":"13","author":"J Hatami","year":"2025","unstructured":"Hatami J, Das K, Wolf L, Aufschnaiter A, Kimpel J, Nolden T, et al. Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype. J Immunother Cancer. 2025;13:e010675.","journal-title":"J Immunother Cancer"},{"key":"1928_CR95","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021;384:1613\u201322.","journal-title":"N Engl J Med"},{"key":"1928_CR96","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","volume":"386","author":"J G\u00e1llego P\u00e9rez-Larraya","year":"2022","unstructured":"G\u00e1llego P\u00e9rez-Larraya J, Garcia-Moure M, Labiano S, Pati\u00f1o-Garc\u00eda A, Dobbs J, Gonzalez-Huarriz M, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med. 2022;386:2471\u201381.","journal-title":"N Engl J Med"},{"key":"1928_CR97","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/oncolo\/oyad041","volume":"28","author":"Y Maruyama","year":"2023","unstructured":"Maruyama Y, Sakurai A, Noda S, Fujiwara Y, Okura N, Takagi T, et al. Regulatory issues: PMDA - review of sakigake designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for malignant glioma. Oncologist. 2023;28:664\u201370.","journal-title":"Oncologist"},{"key":"1928_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102172","volume":"70","author":"A Kaur","year":"2022","unstructured":"Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr Opin Chem Biol. 2022;70:102172.","journal-title":"Curr Opin Chem Biol"},{"key":"1928_CR99","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373\u201384.","journal-title":"Nat Immunol"},{"key":"1928_CR100","doi-asserted-by":"crossref","unstructured":"Ammi R, De Waele J, Willemen Y, Van Brussel I, Schrijvers DM, Lion E, et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther. 2015;146:120\u201331.","DOI":"10.1016\/j.pharmthera.2014.09.010"},{"key":"1928_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412881","volume":"12","author":"J Xiong","year":"2025","unstructured":"Xiong J, Huang J, Xu H, Wu Q, Zhao J, Chen Y, et al. CpG-based nanovaccines enhance ovarian cancer immune response by Gbp2-mediated remodeling of tumor-associated macrophages. Adv Sci. 2025;12:e2412881.","journal-title":"Adv Sci"},{"key":"1928_CR102","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.2025028597","volume":"146","author":"D Dutta","year":"2025","unstructured":"Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, et al. A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma. Blood. 2025;146:2322\u201335.","journal-title":"Blood"},{"key":"1928_CR103","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/med.22016","volume":"44","author":"X Tian","year":"2024","unstructured":"Tian X, Ai J, Tian X, Wei X. cGAS-STING pathway agonists are promising vaccine adjuvants. Med Res Rev. 2024;44:1768\u201399.","journal-title":"Med Res Rev"},{"key":"1928_CR104","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/s41423-020-0456-1","volume":"18","author":"C Fang","year":"2021","unstructured":"Fang C, Mo F, Liu L, Du J, Luo M, Men K, et al. Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cell Mol Immunol. 2021;18:2211\u201323.","journal-title":"Cell Mol Immunol"},{"key":"1928_CR105","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","volume":"20","author":"J Rehwinkel","year":"2020","unstructured":"Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537\u201351.","journal-title":"Nat Rev Immunol"},{"key":"1928_CR106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107\u201312.","journal-title":"Nature"},{"key":"1928_CR107","doi-asserted-by":"crossref","unstructured":"Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477\u201389.","DOI":"10.1038\/s41577-019-0165-0"},{"key":"1928_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122062","volume":"296","author":"S Manna","year":"2023","unstructured":"Manna S, Maiti S, Shen J, Weiss A, Mulder E, Du W, et al. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials. 2023;296:122062.","journal-title":"Biomaterials"},{"key":"1928_CR109","doi-asserted-by":"crossref","unstructured":"Jin MZ, Wang XP. Immunogenic cell death-based cancer vaccines. Front Immunol. 2021;12:697964.","DOI":"10.3389\/fimmu.2021.697964"},{"key":"1928_CR110","doi-asserted-by":"crossref","unstructured":"Hussain Z, Zhang Y, Qiu L, Gou S, Liu K. Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials. NPJ Vaccines. 2025;10:27.","DOI":"10.1038\/s41541-025-01084-2"},{"key":"1928_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887125","volume":"13","author":"Z Deng","year":"2022","unstructured":"Deng Z, Tian Y, Song J, An G, Yang P. mRNA vaccines: the dawn of a new era of cancer immunotherapy. Front Immunol. 2022;13:887125.","journal-title":"Front Immunol"},{"key":"1928_CR112","first-page":"58465","volume":"10","author":"AR Ribeiro","year":"2025","unstructured":"Ribeiro AR, Eguskiza A, Dang H-H, Neuper T, Unger MS, Rodriguez Comas L, et al. Loading of STING agonist into lipid nanoparticles boosts dendritic cell activation. ACS Omega. 2025;10:58465\u201379.","journal-title":"ACS Omega"},{"key":"1928_CR113","doi-asserted-by":"publisher","first-page":"38267","DOI":"10.1021\/acsnano.5c09365","volume":"19","author":"C Zhang","year":"2025","unstructured":"Zhang C, Stewart W, Teng Y, Hu B, Xu X, Zhang X-Q. mRNA-based vaccination drives in vivo dendritic cell reprogramming and selective cytotoxic T lymphocyte modulation for enhanced antitumor immunity. ACS Nano. 2025;19:38267\u201383.","journal-title":"ACS Nano"},{"key":"1928_CR114","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","volume":"25","author":"CY Moon","year":"2025","unstructured":"Moon CY, Belabed M, Park MD, Mattiuz R, Puleston D, Merad M. Dendritic cell maturation in cancer. Nat Rev Cancer. 2025;25:225\u201348.","journal-title":"Nat Rev Cancer"},{"key":"1928_CR115","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21:5047\u201356.","journal-title":"Clin Cancer Res"},{"key":"1928_CR116","doi-asserted-by":"crossref","unstructured":"Cao J, Liao S, Zeng F, Liao Q, Luo G, Zhou Y. Effects of altered glycolysis levels on CD8+ T cell activation and function. Cell Death Dis. 2023;14:407.","DOI":"10.1038\/s41419-023-05937-3"},{"key":"1928_CR117","doi-asserted-by":"crossref","unstructured":"Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo CD4+ T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol. 2020;38:705\u201325.","DOI":"10.1146\/annurev-immunol-103019-085803"},{"key":"1928_CR118","doi-asserted-by":"crossref","unstructured":"Montauti E, Oh DY, Fong L. CD4+ T cells in antitumor immunity. Trends Cancer. 2024;10:969\u201385.","DOI":"10.1016\/j.trecan.2024.07.009"},{"key":"1928_CR119","doi-asserted-by":"crossref","unstructured":"Speiser DE, Chijioke O, Schaeuble K, M\u00fcnz C. CD4+ T cells in cancer. Nat Cancer. 2023;4:317\u201329.","DOI":"10.1038\/s43018-023-00521-2"},{"key":"1928_CR120","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1634\/theoncologist.2011-0122","volume":"17","author":"E Lion","year":"2012","unstructured":"Lion E, Smits ELJM, Berneman ZN, Van Tendeloo VFI. NK cells: key to success of DC-based cancer vaccines? Oncologist. 2012;17:1256\u201370.","journal-title":"Oncologist"},{"key":"1928_CR121","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002054","volume":"32","author":"Y Xia","year":"2020","unstructured":"Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater. 2020;32:e2002054.","journal-title":"Adv Mater"},{"key":"1928_CR122","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev.immunol.021908.132541","volume":"28","author":"T Kurosaki","year":"2010","unstructured":"Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Annu Rev Immunol. 2010;28:21\u201355.","journal-title":"Annu Rev Immunol"},{"key":"1928_CR123","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/1878-0261.13570","volume":"18","author":"H Simon-Molas","year":"2024","unstructured":"Simon-Molas H, Del Prete R, Kabanova A. Glucose metabolism in B cell malignancies: a focus on glycolysis branching pathways. Mol Oncol. 2024;18:1777\u201394.","journal-title":"Mol Oncol"},{"key":"1928_CR124","doi-asserted-by":"crossref","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24:629\u201346.","DOI":"10.1038\/s41568-024-00728-0"},{"key":"1928_CR125","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","volume":"26","author":"T Tsujikawa","year":"2020","unstructured":"Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, et al. Evaluation of cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer. Clin Cancer Res. 2020;26:3578\u201388.","journal-title":"Clin Cancer Res"},{"key":"1928_CR126","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"1928_CR127","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.immuni.2024.06.017","volume":"57","author":"NV Gavil","year":"2024","unstructured":"Gavil NV, Cheng K, Masopust D. Resident memory T cells and cancer. Immunity. 2024;57:1734\u201351.","journal-title":"Immunity"},{"key":"1928_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1843548","volume":"17","author":"T Fourfouris","year":"2026","unstructured":"Fourfouris T, Lee KJ, Hurwitz S, Ahdoot A, Lee A, Zarrabi M, et al. Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy. Front Immunol. 2026;17:1843548.","journal-title":"Front Immunol"},{"key":"1928_CR129","doi-asserted-by":"crossref","unstructured":"Tripathi P, Kurtulus S, Wojciechowski S, Sholl A, Hoebe K, Morris SC, et al. STAT5 is critical to maintain effector CD8+ T cell responses. J Immunol. 2010;185:2116\u201324.","DOI":"10.4049\/jimmunol.1000842"},{"key":"1928_CR130","doi-asserted-by":"crossref","unstructured":"Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002;195:1523\u201332.","DOI":"10.1084\/jem.20020066"},{"key":"1928_CR131","doi-asserted-by":"crossref","unstructured":"Seo H, Chen J, Gonz\u00e1lez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA. 2019;116:12410\u20135.","DOI":"10.1073\/pnas.1905675116"},{"key":"1928_CR132","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm8389","volume":"7","author":"MJ Robinson","year":"2022","unstructured":"Robinson MJ, Dowling MR, Pitt C, O\u2019Donnell K, Webster RH, Hill DL, et al. Long-lived plasma cells accumulate in the bone marrow at a constant rate from early in an immune response. Sci Immunol. 2022;7:eabm8389.","journal-title":"Sci Immunol"},{"key":"1928_CR133","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart P. The role of antigen spreading in the efficacy of immunotherapies. Clin Cancer Res. 2020;26:4442\u20137.","journal-title":"Clin Cancer Res"},{"key":"1928_CR134","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Alles\u00f8e RL, Oliveira G, Li S, Luoma AM, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27:515\u201325.","journal-title":"Nat Med"},{"key":"1928_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29753-z","volume":"13","author":"S Garaud","year":"2022","unstructured":"Garaud S, Dieu-Nosjean M-C, Willard-Gallo K. T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nat Commun. 2022;13:2259.","journal-title":"Nat Commun"},{"key":"1928_CR136","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41423-020-0457-0","volume":"17","author":"L Munoz-Erazo","year":"2020","unstructured":"Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer - considerations for patient prognosis. Cell Mol Immunol. 2020;17:570\u20135.","journal-title":"Cell Mol Immunol"},{"key":"1928_CR137","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","volume":"40","author":"K Li","year":"2022","unstructured":"Li K, Tandurella JA, Gai J, Zhu Q, Lim SJ, Thomas DL, et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 2022;40:1374\u20131391.e7.","journal-title":"Cancer Cell"},{"key":"1928_CR138","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135.","journal-title":"Nature"},{"key":"1928_CR139","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355.","journal-title":"Nature"},{"key":"1928_CR140","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan J-P, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2:794\u2013802.","journal-title":"Nat Cancer"},{"key":"1928_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"1928_CR142","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","volume":"52","author":"R Missiaen","year":"2018","unstructured":"Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol. 2018;52:107\u201316.","journal-title":"Semin Cancer Biol"},{"key":"1928_CR143","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0b013e3181b91c9c","volume":"33","author":"JK Mulligan","year":"2010","unstructured":"Mulligan JK, Rosenzweig SA, Young MRI. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother. 2010;33:126\u201335.","journal-title":"J Immunother"},{"key":"1928_CR144","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080\u20139.","journal-title":"Cancer Sci"},{"key":"1928_CR145","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120:16\u201325.","journal-title":"Br J Cancer"},{"key":"1928_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9:4692.","journal-title":"Nat Commun"},{"key":"1928_CR147","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"1928_CR148","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"1928_CR149","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591\u2013603.","journal-title":"Cancer Res"},{"key":"1928_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60281-8","volume":"16","author":"M Emmers","year":"2025","unstructured":"Emmers M, Welters MJP, Dietz MV, Santegoets SJ, Boekesteijn S, Stolk A, et al. TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study. Nat Commun. 2025;16:4958.","journal-title":"Nat Commun"},{"key":"1928_CR151","doi-asserted-by":"publisher","first-page":"41600","DOI":"10.18632\/oncotarget.6113","volume":"6","author":"S Gebremeskel","year":"2015","unstructured":"Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget. 2015;6:41600\u201319.","journal-title":"Oncotarget"},{"key":"1928_CR152","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843\u201352.","journal-title":"Immunity"},{"key":"1928_CR153","doi-asserted-by":"publisher","first-page":"e011426","DOI":"10.1136\/jitc-2024-011426","volume":"13","author":"S Koido","year":"2025","unstructured":"Koido S, Taguchi J, Shimabuku M, Bito T, Morimoto S, Oji Y, et al. Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms\u2019 tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine. J Immunother Cancer. 2025;13:e011426.","journal-title":"J Immunother Cancer"},{"key":"1928_CR154","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","volume":"27","author":"L Zheng","year":"2021","unstructured":"Zheng L, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL, et al. Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma. Clin Cancer Res. 2021;27:1278\u201386.","journal-title":"Clin Cancer Res"},{"key":"1928_CR155","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer P, Paraschiakos T, Windhorst S. Oncogenic activity and cellular functionality of melanoma associated antigen A3. Biochem Pharmacol. 2021;192:114700.","DOI":"10.1016\/j.bcp.2021.114700"},{"key":"1928_CR156","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183:347\u2013362.e24.","journal-title":"Cell"},{"key":"1928_CR157","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 2024;14:2209\u201323.","journal-title":"Cancer Discov"},{"key":"1928_CR158","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2174\/0115680096360059250131075456","volume":"25","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Sultana A, Bisht AS, Gupta G. Groundbreaking mRNA lung cancer vaccine trials: a new dawn in cancer treatment. Curr Cancer Drug Targets. 2025;25:962\u20137.","journal-title":"Curr Cancer Drug Targets"},{"key":"1928_CR159","doi-asserted-by":"crossref","unstructured":"Zhang Y, Hu YF, Ma L, Wu Y, Chao D, Chen X, et al. A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. Front Immunol. 2025;16:1538032.","DOI":"10.3389\/fimmu.2025.1538032"},{"key":"1928_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39196-9","volume":"14","author":"T Heumann","year":"2023","unstructured":"Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. 2023;14:3650.","journal-title":"Nat Commun"},{"key":"1928_CR161","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00262-012-1261-1","volume":"61","author":"H Ardon","year":"2012","unstructured":"Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I\/II trial. Cancer Immunol Immunother. 2012;61:2033\u201344.","journal-title":"Cancer Immunol Immunother"},{"key":"1928_CR162","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"R Fu","year":"2024","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J, et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9:118.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01928-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01928-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01928-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:47:37Z","timestamp":1793335657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01928-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":162,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01928-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}